Fox Run Management, L.L.C. Chinook Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

  • $517 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$21.53 - $26.8 $122,742 - $152,786
5,701 Added 73.69%
13,437 $311,000
Q4 2022

Feb 07, 2023
SELL
$18.63 - $27.35 $220,392 - $323,550
-11,830 Reduced 60.46%
7,736 $202,000
Q3 2022

Nov 07, 2022
BUY
$17.51 - $23.37 $342,600 - $457,257
19,566 New
19,566 $385,000

Others Institutions Holding KDNY

# of Institutions
5
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email